AVLAYAH® (tividenofusp alfa-eknm) net product revenue accelerated to $17.8 million in its second full commercial quarterContinued growth expectations drive Q4 2026 net product revenue guidance of $30.0 million to $32.0
First FDA-approved biologic specifically designed to cross blood-brain barrier wins award dedicated to exceptional scientific leadership and transformational impact on patient careFirst new FDA-approved treatment option
SOUTH SAN FRANCISCO, Calif., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ:DNLI) today announced that it will report financial results and business highlights for the third quarter ended September
Strong first full quarter of AVLAYAH™ (tividenofusp alfa-eknm) launch generated $3.6 million in net product revenueAdvanced TransportVehicle™ portfolio with two Alzheimer’s disease programs now in clinical
SOUTH SAN FRANCISCO, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ:DNLI) today announced that it will report financial results and business highlights for the second quarter ended June 30,
Denali co-founder and CEO Ryan Watts, Ph.D., to deliver opening plenary address at 2026 AAIC in London on July 12, 2026Presentation will highlight recent scientific advances and future opportunities to accelerate
Proceeds from transaction to support advancement of Denali's broad TransportVehicle™-enabled clinical portfolio for lysosomal storage disorders and neurodegenerative diseasesDenali was awarded Priority Review
The Phase 2b LUMA study of BIIB122 in early-stage Parkinson's disease did not meet its primary or secondary endpoints Based on data from the Phase 2b LUMA study, Biogen and Denali will discontinue development of BIIB122
FDA approved AVLAYAH™ (tividenofusp alfa-eknm) for treatment of Hunter syndrome (MPS II) and as first medicine to leverage transferrin receptor to cross blood-brain barrierAVLAYAH launched in U.S. with strong
AUSTIN, Texas, April 20, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Biotechnology is undergoing a quiet but profound transformation, one that is reshaping how investors understand value in a sector
Denali plans to continue clinical development of DNL593, which is designed to deliver progranulin to the brain using TransportVehicle™ technologyResults from ongoing Phase 1/2 study in patients with FTD-GRN
Issued on behalf of Avaí Bio, Inc.USANewsGroup.comVANCOUVER, BC, March 31, 2026 /CNW/ -- The FDA has approved more than 40 cell and gene therapy products. The regenerative medicine market is projected to reach $578
First new FDA-approved treatment option in nearly 20 years for families living with this rare lysosomal storage diseaseFirst FDA-approved medicine in emerging new class of biotherapeutics that leverage transferrin
Issued on behalf of Avaí Bio, Inc.VANCOUVER, BC, March 24, 2026 /CNW/ -- USANewsGroup.com — The FDA has approved more than 40 cell and gene therapy products. The regenerative medicine market is projected to reach $578
Tividenofusp alfa (DNL310; ETV:IDS) launch readiness established ahead of April 5, 2026 Prescription Drug User Fee Act (PDUFA) target action date for Hunter syndromeDNL126 (ETV:SGSH) Phase 1/2 preliminary data presented
